-
公开(公告)号:EP4172141A1
公开(公告)日:2023-05-03
申请号:EP21735721.9
申请日:2021-06-28
申请人: Synaffix B.V.
IPC分类号: C07C307/04 , C07D207/46 , A61K47/50
-
公开(公告)号:EP0896531A4
公开(公告)日:2002-10-30
申请号:EP96929723
申请日:1996-08-21
发明人: WIDDOWSON KATHERINE LOUISA , VEBER DANIEL FRANK , JUREWICZ ANTHONY JOSEPH , RUTLEDGE MELVIN CLARENCE JR , HERTZBERG ROBERT PHILIP
IPC分类号: A61K31/17 , A61K31/18 , A61K31/223 , A61K31/275 , A61K31/277 , A61K31/36 , A61K31/381 , A61K31/426 , A61K31/47 , A61P29/00 , A61P37/00 , C07C253/14 , C07C255/53 , C07C275/34 , C07C275/36 , C07C275/38 , C07C275/40 , C07C275/42 , C07C307/04 , C07C307/10 , C07C309/15 , C07C311/10 , C07C311/13 , C07C311/15 , C07C311/21 , C07C311/29 , C07C311/46 , C07C317/42 , C07C323/44 , C07C335/16 , C07C335/18 , C07D213/30 , C07D213/71 , C07D215/36 , C07D217/02 , C07D277/36 , C07D277/46 , C07D317/66 , C07D333/28 , C07D333/34 , C07D333/36 , C07D409/04
CPC分类号: C07D213/30 , A61K31/17 , A61K31/18 , A61K31/223 , A61K31/275 , A61K31/277 , A61K31/36 , A61K31/381 , A61K31/426 , A61K31/47 , C07C275/34 , C07C275/38 , C07C275/40 , C07C275/42 , C07C307/10 , C07C309/15 , C07C311/10 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/46 , C07C317/42 , C07C323/44 , C07C335/18 , C07C2602/08 , C07C2603/18 , C07D213/71 , C07D215/36 , C07D217/02 , C07D277/36 , C07D277/46 , C07D317/66 , C07D333/28 , C07D333/34 , C07D333/36 , C07D409/04
摘要: This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
摘要翻译: 本发明涉及苯脲类治疗由趋化因子介导的疾病状态白细胞介素-8(IL-8)的新用途。
-
公开(公告)号:EP0557122B1
公开(公告)日:1997-01-15
申请号:EP93301235.3
申请日:1993-02-19
IPC分类号: C07C307/04 , C07D207/26 , C07D207/12 , C07D501/04 , C07D477/00
CPC分类号: C07D207/273 , C07C307/04 , C07D207/12 , C07D477/02 , C07D477/14 , C07D477/20 , C07D501/00 , C08L63/00 , Y02P20/55
-
公开(公告)号:EP3833323A1
公开(公告)日:2021-06-16
申请号:EP19848154.1
申请日:2019-08-08
IPC分类号: A61K8/34 , A61K31/70 , A61P35/00 , C07C211/44 , C07C211/50 , C07C307/04
-
公开(公告)号:EP2800740A1
公开(公告)日:2014-11-12
申请号:EP12824810.1
申请日:2012-12-21
申请人: Pfizer Limited
发明人: BROWN, Alan Daniel , GALAN, Sebastien Rene Gabriel , MILLAN, David Simon , RAWSON, David James , STORER, Robert Ian , STUPPLE, Paul Anthony , SWAIN, Nigel Alan
IPC分类号: C07D213/74 , C07C307/04 , C07C307/06 , C07D401/04 , C07D401/12 , C07D237/08 , C07D205/04 , C07D213/643 , C07D213/69 , C07B59/00 , A61K31/506 , A61K31/44 , A61K31/277 , A61K31/165 , A61P29/00
CPC分类号: C07C307/06 , A61K31/165 , A61K31/397 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/50 , C07B59/002 , C07B2200/05 , C07C307/04 , C07C2601/02 , C07C2603/62 , C07D205/04 , C07D213/643 , C07D213/65 , C07D213/69 , C07D213/74 , C07D237/08 , C07D401/04 , C07D401/12
摘要: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z, R
1a , R
1b , R
2 , R
3 , R
4 and R
5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.摘要翻译: 本发明涉及式(I)的磺酰胺衍生物:或其药学上可接受的盐,其中Z,R 1a,R 1b,R 2,R 3,R 4和R 5如说明书中所定义,以及它们在药物中的用途, 包含它们,其制备过程和在这些过程中使用的中间体。 式(I)化合物是可用于治疗各种疾病,特别是疼痛的Nav1.7抑制剂。
-
公开(公告)号:EP1363876B1
公开(公告)日:2009-07-29
申请号:EP02714910.3
申请日:2002-02-12
申请人: KARO BIO AB
IPC分类号: C07C307/04 , C07C311/08 , A61K31/18 , A61P3/10
CPC分类号: C07D295/088 , C07C307/10 , C07C311/08 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/18
摘要: Compounds of formula (I) (I), or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.
-
公开(公告)号:EP0557122A1
公开(公告)日:1993-08-25
申请号:EP93301235.3
申请日:1993-02-19
IPC分类号: C07C307/04 , C07D207/26 , C07D207/12 , C07D501/04 , C07D477/00
CPC分类号: C07D207/273 , C07C307/04 , C07D207/12 , C07D477/02 , C07D477/14 , C07D477/20 , C07D501/00 , C08L63/00 , Y02P20/55
摘要: The method for producing a sulfamide according to the present invention includes the step of reacting an alcohol and an oxycarbonylsulfamide compound in the presence of a trivalent phosphorus compound and an azodicarboxylic acid derivative. In one embodiment, the sulfamide is represented by Formula I, the alcohol is represented by Formula II, and the oxycarbonylsulfamide compound is represented by Formula III:
R³NHSO₂NR¹R² (I)
wherein R¹ and R² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, a heterocyclic group, and alkyl substituted with the heterocyclic group, respectively, said heterocyclic group being selected from the group consisting of pyranosyl, furanosyl, piperidinyl, pyrrolidinyl, an azetidinone ring, a cephem ring, a penem ring, and a carbapenem ring; R³ is selected from the group consisting of alkyl, alkenyl, alkynyl, aralkyl, a heterocyclic group, alkyl substituted with the heterocyclic group, and pyrrolidinyl-methyl, said heterocyclic group being selected from the group consisting of pyranosyl, furanosyl, piperidinyl, pyrrolidinyl, an azetidinone ring, a cephem ring, a penem ring, and a carbapenem ring;
R³OH (II)
wherein R³ is defined as above;
R⁴OOC-NHSO₂NR¹R² (III)
wherein R¹ and R² are defined as above; and R⁴ is a carboxy protecting group.摘要翻译: 根据本发明的磺酰胺的制备方法包括在三价磷化合物和偶氮二羧酸衍生物的存在下使醇和氧羰基磺酰胺化合物反应的步骤。 在一个实施方案中,磺酰胺由式I表示,醇由式II表示,氧羰基磺酰胺化合物由式III表示:R 3 NHSO 2 NR 1 R 2(I)其中R 1, R 2独立地选自氢,烷基,环烷基,烯基,炔基,芳烷基,芳基,杂环基和被杂环基取代的烷基,所述杂环基选自 吡喃糖基,哌啶基,吡咯烷基,氮杂环丁酮环,头孢烯环,青霉烯环和碳青霉烯环; R 3选自烷基,烯基,炔基,芳烷基,杂环基,被杂环基取代的烷基和吡咯烷基 - 甲基,所述杂环基选自吡喃糖基,呋喃糖基,哌啶基 吡咯烷基,氮杂环丁酮环,头孢烯环,青霉烯环和碳青霉烯环; R 3 OH(II)其中R 3如上定义; R 4 OOC-NHSO 2 NR R 2(III)其中R 1和R 2如上定义; R 4为羧基保护基。
-
公开(公告)号:EP0507277A1
公开(公告)日:1992-10-07
申请号:EP92105614.9
申请日:1992-04-01
IPC分类号: C07D239/52 , C07C333/12 , C07C307/04 , C07D295/215
CPC分类号: C07D521/00 , C07C311/54 , C07C333/12
摘要: Das erfindungsgemäße Verfahren zur Herstellung von Verbindungen der Formel (I) oder deren Salzen,
worin X = -O-, -O-NR²- oder -SO₂-NR²-, Y N oder CH,
R¹ ein (subst.) Alkyl-, (subst.) Alkenyl- oder (subst.) Alkinyl-Rest, oder, im Falle von X = O, auch (subst.) Phenyl und
R²H, Alkyl, Alkenyl, Alkinyl oder Cycloalkyl bedeuten sowie R³, R⁴, R⁵ und R⁶ wie in Formel I nach Anspruch 1 definiert sind,
ist dadurch gekennzeichnet, daß man Verbindungen der Formel II,
worin Z -S-, -NR⁸- und R⁷, R⁸ = H, Alkyl, (subst.) Phenyl oder (subst.) Benzyl oder, im Falle Z = NR⁸, R⁷ und NR⁸ auch einen 5- bis 7-gliedrigen Heterocyclus bedeuten, mit Verbindungen der Formel III umsetzt.摘要翻译: 根据本发明的制备式(I)化合物或其盐的方法,其中X = -O-,-O-NR 2 - 或-SO 2 -NR 2 - ,Y (取代的)烷基,(取代的)烯基或(取代的)炔基,或者如果X = O,也是(取代的)苯基,R 2是H,烷基, 烯基,炔基或环烷基,R 3,R 4,R 5和R 6如权利要求1所述的式I中所定义,其特征在于式II化合物 其中Z是-S-,-NR 8 - ,R 7和R 8是H,烷基,(取代的)苯基或(取代的)苄基,或者如果Z = NR 8, 7>和NR 8也表示5至7元杂环,与式III化合物反应。
-
公开(公告)号:EP2546256B1
公开(公告)日:2019-10-09
申请号:EP12172363.9
申请日:2008-08-01
发明人: Armitage, Ian , Elliot, Eric L. , Langston, Marianne , Langston, Steven , McCubbin, Quentin J. , Mizutani, Hirotake , Stirling, Matthew , Zhu, Lei
IPC分类号: C07D487/04 , C07C215/44 , C07C217/52 , C07C219/24 , C07C307/04
-
10.
公开(公告)号:EP2970116A1
公开(公告)日:2016-01-20
申请号:EP14709306.6
申请日:2014-03-12
IPC分类号: C07C303/40 , C07C307/04 , C07C307/06 , C07C307/08 , C07C311/03 , C07C311/08 , C07C311/22 , C07C311/30 , C07D241/04 , C07D417/10 , C07D417/12 , C07D285/04 , C07D285/06 , C07D285/16 , C07D285/36
CPC分类号: C07D417/12 , C07D211/96 , C07D285/16 , C07D285/36 , C07D295/185 , C07D401/12
摘要: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
摘要翻译: 其中m,n,p,q,r,A,X 1,X 2,X 3,X 4,X 5,X 6,Y,Z,G,R 1a,R 2a,R 1b,R 2b,R 3,R 4,R 5和R 6如本文所定义。 还公开了制备所述化合物和使用所述化合物治疗炎性疾病如关节炎的方法。
-
-
-
-
-
-
-
-
-